Used in the development of antidiabetic agents, particularly as a PPARγ (peroxisome proliferator-activated receptor gamma) agonist. It helps improve insulin sensitivity in type 2 diabetes by regulating genes involved in glucose and lipid metabolism. Its structure supports binding to nuclear receptors that modulate metabolic pathways, making it a candidate for insulin resistance treatment. Research focuses on optimizing its efficacy and reducing side effects compared to existing thiazolidinedione drugs.